Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC-1532-GUCG darolutamide vs ADT in hormone-naive prostate cancer
2024-510840-30-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: PSA response at 24 weeks (darolutamide arm). Planned start May 2024; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-510840-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510840-30-00.